Fulton Bank N.A. Purchases Shares of 61,231 Kenvue Inc. (NYSE:KVUE)

Fulton Bank N.A. acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 61,231 shares of the company's stock, valued at approximately $1,318,000.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Dfpg Investments LLC boosted its position in shares of Kenvue by 2.3% during the 4th quarter. Dfpg Investments LLC now owns 26,659 shares of the company's stock valued at $567,000 after acquiring an additional 589 shares during the last quarter. Mutual Advisors LLC boosted its position in shares of Kenvue by 6.1% during the 4th quarter. Mutual Advisors LLC now owns 10,606 shares of the company's stock valued at $228,000 after acquiring an additional 612 shares during the last quarter. Baron Wealth Management LLC boosted its position in shares of Kenvue by 7.5% during the 4th quarter. Baron Wealth Management LLC now owns 12,915 shares of the company's stock valued at $278,000 after acquiring an additional 899 shares during the last quarter. Arete Wealth Advisors LLC boosted its position in shares of Kenvue by 5.7% during the 3rd quarter. Arete Wealth Advisors LLC now owns 18,835 shares of the company's stock valued at $378,000 after acquiring an additional 1,016 shares during the last quarter. Finally, Clearstead Advisors LLC bought a new position in shares of Kenvue during the 3rd quarter valued at approximately $25,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE traded up $0.08 during trading on Friday, reaching $20.25. 11,312,970 shares of the stock were exchanged, compared to its average volume of 16,665,205. The business's 50 day moving average price is $20.01 and its two-hundred day moving average price is $20.22. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to analysts' expectations of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. Kenvue's revenue for the quarter was down 2.7% on a year-over-year basis. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.17 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend was Tuesday, February 13th.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on KVUE. The Goldman Sachs Group began coverage on Kenvue in a research report on Friday, March 1st. They set a "neutral" rating and a $20.00 target price for the company. UBS Group lifted their target price on Kenvue from $20.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, December 19th. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an "outperform" rating for the company in a research report on Friday, February 9th. JPMorgan Chase & Co. decreased their target price on Kenvue from $25.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 9th. Finally, William Blair started coverage on Kenvue in a research report on Wednesday. They set a "market perform" rating for the company. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $25.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.